Efruxifermin

Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21) . Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis[1].

Product Specifications

CAS Number

[2375240-92-7]

Product Name Alternative

AKR-001; AMG-876

UNSPSC

12352203

Target

FGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/efruxifermin.html

Purity

98.58

Solubility

10 mM in DMSO

Smiles

[Efruxifermin]

Molecular Weight

(91.863 kDa)

References & Citations

[1]Tillman EJ, et al. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol. 2022 Apr;179 (7) :1384-1394.